文献速递前列腺癌

循环雄激素受体在前列腺癌预后与治疗选择中的应用

Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2021-01-09

本文分析血浆DNA中雄激素受体(AR)状态(尤其AR拷贝数)作为微创方法识别去势抵抗性前列腺癌(CRPC)患者启动恩扎卢胺或阿比特龙时治疗耐药的潜力。血浆AR升高的患者在接受紫杉烷类治疗时结局不劣于血浆AR正常者,提示循环AR有助于在AR靶向治疗与紫杉烷类之间优化临床决策,并可能指导调整紫杉烷方案。证据表明循环AR在CRPC全程管理中可能发挥作用,早期检测、疾病监测及多重生物标志物策略中的应用前景值得期待,但需前瞻性试验验证。

要点

  • 血浆AR拷贝数检测可微创识别CRPC患者对恩扎卢胺或阿比特龙的潜在耐药。
  • 血浆AR升高者接受紫杉烷类治疗时结局不劣于血浆AR正常者。
  • 循环AR有望指导AR靶向治疗与紫杉烷类之间的治疗选择,但需前瞻性验证。

核心结论

  • 循环AR可能改善CRPC患者在AR靶向治疗与紫杉烷类之间的临床决策,并可能指导调整紫杉烷方案。
  • 证据表明循环AR在CRPC全程管理中可能发挥作用。
  • 血浆AR检测在早期前列腺癌、疾病监测及多重生物标志物策略中具有前景,但需前瞻性试验验证。

研究设计与样本

  • 本文为综述性分析,聚焦血浆DNA中雄激素受体(AR)状态(尤其AR拷贝数)作为微创方法在CRPC治疗选择中的应用。

主要发现

  • 血浆AR升高患者在接受紫杉烷类治疗时结局不劣于血浆AR正常患者。
  • 血浆AR检测有望用于识别启动恩扎卢胺或阿比特龙时的治疗耐药。

临床怎么用

  • 循环AR检测可能辅助在AR靶向治疗与紫杉烷类之间进行临床决策。
  • 循环AR可能用于指导调整紫杉烷方案(适应性与标准方案之间)。
  • 血浆AR检测的临床意义尚需前瞻性试验验证后方可常规应用。

局限性

  • 需前瞻性试验验证现有发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Analysis of androgen receptor (AR) status, particularly AR copy number, in plasma DNA is a minimally invasive method with the potential to identify treatment resistance in patients with castration-resistant prostate cancer (CRPC) starting enzalutamide or abiraterone. Patients with elevated plasma AR do not have worse outcomes than patients with normal plasma AR when treated with taxanes. Consequently, circulating AR may improve clinical decision-making between AR-directed therapies versus taxanes and probably also between adapted versus standard taxane regimens. The evidence indicates that circulating AR could have a role in overall CRPC management. Promising clinical implications of plasma AR testing are measurement in earlier stages of prostate cancer, disease monitoring, and within the context of a multiplex biomarker strategy to improve treatment selection for CRPC patients. PATIENT SUMMARY: Measurement of the copy number of androgen receptor genes in plasma is a promising tool for guiding personalised treatment in patients with castration-resistant prostate cancer. However, prospective trials to validate these findings are needed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Conteduca V, Wetterskog D, Gonzalez-Billalabeitia E, et al. Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. Eur Urol Oncol. 2021. PMID: 33436326. doi:10.1016/j.euo.2020.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。